What's Happening?
Clinical research sites are experiencing increasing strain due to the growing complexity of clinical trials, with 41% now identifying it as their top operational problem, an increase from 35% a year ago. According to WCG’s fourth annual Clinical Research
Site Challenges Report, two-thirds of sites report their teams are overloaded or at risk of burnout, and fewer than a third consider their current workload sustainable. Protocol design is a primary driver of this difficulty, with 66% of sites rating protocol complexity as a high factor, up from 59% in 2025. Sponsor-driven design changes lead to amendments at 78% of sites, with 55% spending at least a fifth of their start-up period processing these changes. This contributes to over half of sites taking three months or longer to complete study start-up. The report also notes that only 16% of sites have implemented AI or automation, yet 44% are already encountering AI-related clauses in their clinical trial agreements, indicating legal obligations are outpacing operational readiness. Sites see the greatest potential for AI in participant recruitment (36%) and integrated systems to eliminate duplicate data entry (35%).
Why It's Important?
The escalating complexity and operational strain on U.S. clinical research sites pose a significant threat to the efficiency and pace of drug development. Delays in trial start-up and execution directly impact the timeline for new therapies to reach patients, potentially increasing healthcare costs and hindering medical advancements. The high rates of burnout among research staff could lead to a shortage of skilled professionals, further exacerbating the problem. The disconnect between the rapid introduction of AI-related clauses in agreements and the slow adoption of AI tools by sites creates a compliance and operational challenge. While AI offers promising solutions for participant recruitment and data management, the current implementation gap means sites are burdened with new requirements without the tools to meet them effectively. This situation affects pharmaceutical companies, contract research organizations (CROs), and ultimately, patients who rely on timely and well-executed clinical trials for access to innovative treatments.
What's Next?
To alleviate the strain on clinical research sites and improve trial efficiency, the report suggests that sponsors need to prioritize intervention in protocol design. Simplifying protocols before studies reach sites could significantly reduce the burden of amendments and accelerate start-up times. For AI integration, there's a clear need for better alignment between legal requirements and operational capabilities. Sponsors and technology providers may need to offer more accessible and user-friendly AI solutions, along with training and support, to help sites effectively implement these tools. The identified potential of AI in participant recruitment and integrated data systems indicates areas where focused investment and development could yield substantial benefits. Addressing these challenges will require collaborative efforts from sponsors, CROs, technology developers, and regulatory bodies to create a more sustainable and efficient clinical trial ecosystem in the U.S.
Beyond the Headlines
The growing complexity of clinical trials and the uneven integration of AI highlight a broader systemic issue within medical research: the tension between scientific advancement and operational feasibility. The rapid evolution of scientific protocols, while necessary for cutting-edge research, often outpaces the capacity of existing infrastructure and human resources. The premature introduction of AI clauses without corresponding operational readiness could lead to a 'digital divide' among research sites, where those with resources to adopt AI thrive, while others fall behind, potentially impacting diversity and access to trials. This situation also raises questions about the long-term sustainability of the current clinical trial model. A fundamental re-evaluation of how trials are designed, funded, and executed, with a greater emphasis on site-centric solutions and integrated technological support, may be necessary to prevent a crisis in clinical research and ensure that the promise of new therapies can be realized efficiently and equitably.
